PMID- 36445856
OWN - NLM
STAT- MEDLINE
DCOM- 20221201
LR  - 20230106
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 17
IP  - 11
DP  - 2022
TI  - Interleukin-1beta triggers matrix metalloprotease-3 expression through p65/RelA 
      activation in melanoma cells.
PG  - e0278220
LID - 10.1371/journal.pone.0278220 [doi]
LID - e0278220
AB  - Melanoma shows highly aggressive behavior (i.e., local invasion and metastasis). 
      Matrix metalloprotease-3 (MMP-3), a zinc-dependent endopeptidase, degrades 
      several extracellular substrates and contributes to local invasion by creating a 
      microenvironment suitable for tumor development. Here, we report that 
      interleukin-1beta (IL-1beta) triggers the MMP-3 expression in canine melanoma cells. 
      The activity of MMP-3 in the culture supernatant was increased in IL-1beta-treated 
      melanoma cells. IL-1beta time- and dose-dependently provoked the mRNA expression of 
      MMP-3. IL-1beta induced the migration of melanoma cells; however, this migration was 
      attenuated by UK356618, an MMP-3 inhibitor. When the cells were treated with the 
      nuclear factor-kappaB (NF-kappaB) inhibitor TPCA-1, the inhibition of MMP-3 expression 
      was observed. In IL-1beta-treated cells, the phosphorylation both of p65/RelA and 
      p105 was detected, indicating NF-kappaB pathway activation. In p65/RelA-depleted 
      melanoma cells, IL-1beta-mediated mRNA expression of MMP-3 was inhibited, whereas 
      this reduction was not observed in p105-depleted cells. These findings suggest 
      that MMP-3 expression in melanoma cells is regulated through IL-1beta-mediated 
      p65/RelA activation, which is involved in melanoma cell migration.
CI  - Copyright: (c) 2022 Nunomura et al. This is an open access article distributed 
      under the terms of the Creative Commons Attribution License, which permits 
      unrestricted use, distribution, and reproduction in any medium, provided the 
      original author and source are credited.
FAU - Nunomura, Junichi
AU  - Nunomura J
AD  - Laboratories of Veterinary Radiotherapy, Nihon University College of Bioresource 
      Sciences, Fujisawa, Kanagawa, Japan.
FAU - Nakano, Rei
AU  - Nakano R
AUID- ORCID: 0000-0003-0255-6347
AD  - Laboratories of Veterinary Radiotherapy, Nihon University College of Bioresource 
      Sciences, Fujisawa, Kanagawa, Japan.
AD  - Laboratory for Mucosal Immunity, Center for Integrative Medical Sciences, RIKEN 
      Yokohama Institute, Yokohama, Kanagawa, Japan.
AD  - Japan Animal Specialty Medical Institute, Tsuzuki, Yokohama, Kanagawa, Japan.
FAU - Naruke, Atsuto
AU  - Naruke A
AD  - Laboratories of Veterinary Radiotherapy, Nihon University College of Bioresource 
      Sciences, Fujisawa, Kanagawa, Japan.
FAU - Suwabe, Yoko
AU  - Suwabe Y
AD  - Laboratories of Veterinary Radiotherapy, Nihon University College of Bioresource 
      Sciences, Fujisawa, Kanagawa, Japan.
FAU - Nakano, Masumi
AU  - Nakano M
AD  - Laboratories of Veterinary Radiotherapy, Nihon University College of Bioresource 
      Sciences, Fujisawa, Kanagawa, Japan.
FAU - Yachiku, Naoya
AU  - Yachiku N
AD  - Laboratories of Veterinary Radiotherapy, Nihon University College of Bioresource 
      Sciences, Fujisawa, Kanagawa, Japan.
FAU - Kuji, Manami
AU  - Kuji M
AD  - Laboratories of Veterinary Radiotherapy, Nihon University College of Bioresource 
      Sciences, Fujisawa, Kanagawa, Japan.
FAU - Sugimura, Mana
AU  - Sugimura M
AD  - Laboratories of Veterinary Radiotherapy, Nihon University College of Bioresource 
      Sciences, Fujisawa, Kanagawa, Japan.
FAU - Namba, Shinichi
AU  - Namba S
AUID- ORCID: 0000-0002-9182-3656
AD  - Laboratories of Veterinary Radiotherapy, Nihon University College of Bioresource 
      Sciences, Fujisawa, Kanagawa, Japan.
FAU - Kitanaka, Taku
AU  - Kitanaka T
AD  - Laboratories of Veterinary Radiotherapy, Nihon University College of Bioresource 
      Sciences, Fujisawa, Kanagawa, Japan.
FAU - Kitanaka, Nanako
AU  - Kitanaka N
AD  - Laboratories of Veterinary Radiotherapy, Nihon University College of Bioresource 
      Sciences, Fujisawa, Kanagawa, Japan.
FAU - Sugiya, Hiroshi
AU  - Sugiya H
AD  - Laboratories of Veterinary Radiotherapy, Nihon University College of Bioresource 
      Sciences, Fujisawa, Kanagawa, Japan.
AD  - Japan Animal Specialty Medical Institute, Tsuzuki, Yokohama, Kanagawa, Japan.
FAU - Nakayama, Tomohiro
AU  - Nakayama T
AD  - Laboratories of Veterinary Radiotherapy, Nihon University College of Bioresource 
      Sciences, Fujisawa, Kanagawa, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20221129
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
RN  - 0 (Interleukin-1beta)
RN  - 0 (NF-kappa B)
RN  - 0 (I-kappa B Proteins)
RN  - 0 (RNA, Messenger)
SB  - IM
MH  - Animals
MH  - Dogs
MH  - *Matrix Metalloproteinase 3/genetics
MH  - Interleukin-1beta/pharmacology
MH  - NF-kappa B
MH  - I-kappa B Proteins
MH  - *Melanoma
MH  - RNA, Messenger
MH  - Tumor Microenvironment
PMC - PMC9707762
COIS- The authors have declared that no competing interests exist.
EDAT- 2022/11/30 06:00
MHDA- 2022/12/02 06:00
PMCR- 2022/11/29
CRDT- 2022/11/29 13:32
PHST- 2022/07/14 00:00 [received]
PHST- 2022/11/11 00:00 [accepted]
PHST- 2022/11/29 13:32 [entrez]
PHST- 2022/11/30 06:00 [pubmed]
PHST- 2022/12/02 06:00 [medline]
PHST- 2022/11/29 00:00 [pmc-release]
AID - PONE-D-22-19674 [pii]
AID - 10.1371/journal.pone.0278220 [doi]
PST - epublish
SO  - PLoS One. 2022 Nov 29;17(11):e0278220. doi: 10.1371/journal.pone.0278220. 
      eCollection 2022.